Blackstone Life Sciences β Full Portfolio
5 tracked investments Β· listed companies and verified rows first
AvenCell Therapeutics develops next-generation cell therapies for hard-to-treat cancers, including solid tumors, combining switchable universal CAR-T technology with a CRISPR/Cas9-based allogeneic platform.
BiotechLongevityMedical Devices
Andrew Schiermeier(Chief Executive Officer)in
Co-investorsNovo HoldingsEight Roads VenturesF-Prime CapitalNYBC Ventures
Alnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.
BiotechDigital HealthMedical Devices
John Maraganore(Founder)inDr. Yvonne Greenstreetin
Co-investorsARCH Venture PartnersAtlas VentureCardinal Partners
Anagram runs the full insurance revenue cycle for eye care practices, handling eligibility and benefits checks, claim scrubbing and submission, denial management, and payment posting and reconciliation across both vision and medical insurance.
HealthtechInsurTechSaaS
Co-investorsGreatPoint VenturesHealthy VenturesManchesterStory Group, LLCKEC VenturesKickstartNextView Ventures+1 more
Founded by BXLS with Novartis in February 2019 to advance next-generation targeted therapies for high-risk cardiovascular patients; sold to Novartis in April 2025.
Moderna develops mRNA-based medicines for infectious and serious diseases using its proprietary mRNA platform and design technology.
BiotechDeep TechMedical DevicesCambridge, US
Robert Langer(Director)Lorence Kim(Executive Officer)James R. Kasinger(Executive Officer)Stephen Hoge(Executive Officer)Theo Melas-Kyriazi(Director)Robert Carpenter(Director)
Co-investorsAglae VenturesFlagship PioneeringFPVKhosla VenturesPremji InvestRA Capital
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.